Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
11.64
Nov 18 • 3:59 PM ET Dollar change-0.27 Percentage change(-2.27%)
Aftermarket Close
11.62
Aftermarket • 5:40 PM ET Dollar change-0.02 Percentage change(-0.17%)
Index
-
Market Cap
1.51B
Enterprise Value
1.54B
Income
-57.63M
Sales
120.57M
Book/sh
4.38
Cash/sh
0.79
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
108
IPO
Jan 18, 2006
P/E
-
Forward P/E
51.46
PEG
-
P/S
12.56
P/B
2.66
P/C
14.72
P/FCF
-
EV/EBITDA
-
EV/Sales
12.76
Quick Ratio
2.09
Current Ratio
2.43
Debt/Eq
0.22
LT Debt/Eq
0.20
Option/Short
Yes / Yes
EPS (ttm)
-0.45
EPS next Y
0.23
EPS next Q
-0.08
EPS this Y
54.80%
EPS next Y
212.70%
EPS next 5Y
-
EPS past 3/5Y
24.72% 22.09%
Sales past 3/5Y
152.90% 74.52%
EPS Y/Y TTM
47.33%
Sales Y/Y TTM
600.89%
EPS Q/Q
12.33%
Sales Q/Q
-5.36%
Insider Own
-
Insider Trans
-
Inst Own
3.39%
Inst Trans
-17.79%
ROA
-7.40%
ROE
-9.89%
ROIC
-8.45%
Gross Margin
84.10%
Oper. Margin
-42.63%
Profit Margin
-47.80%
SMA20
-14.11%
SMA50
-17.10%
SMA200
-23.06%
Trades
Shs Outstand
130.11M
Shs Float
128.29M
52W High
21.50 -45.86%
52W Low
11.74 -0.85%
Volatility
4.39% 3.73%
ATR (14)
0.64
RSI (14)
33.51
Beta
2.27
Rel Volume
0.55
Avg Volume
239.97K
Volume
132,577
Perf Week
-14.73%
Perf Month
-6.20%
Perf Quarter
-33.22%
Perf Half Y
-19.83%
Perf YTD
-35.48%
Perf Year
-21.83%
Perf 3Y
393.22%
Perf 5Y
-7.91%
Perf 10Y
22.01%
Prev Close
11.91
Price
11.64
Change %
-2.27%
Consensus
Strong Buy
Avg. Price Target
$30.21
Implied Upside
+159.5%
Analysts7incl. previous ratings
Rating Distribution4 Buy · 2 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 25, 2025Upgrade
JEF logoJJefferies
Hold → Buy
Jul 18, 2025Downgrade
JEF logoJJefferies
Buy → Hold
Dec 23, 2024Downgrade
JEF logoJJefferies
Buy → Hold
Sep 24, 2024Upgrade
MMaxim Group
Hold → Buy$12+3.1%
Aug 29, 2024Upgrade
JEF logoJJefferies
Hold → Buy
Jul 23, 2024Upgrade
PPiper Sandler
Neutral → Overweight$4 → $11-5.5%
Aug 31, 2023Upgrade
JEF logoJJefferies
Hold → Buy
Aug 07, 2023Downgrade
MMaxim Group
Buy → Hold
Aug 04, 2023Downgrade
WWilliam Blair
Outperform → Mkt Perform
Aug 04, 2023Downgrade
PPiper Sandler
Overweight → Neutral$7 → $2-82.8%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
George GregoryDirectorApr 04 '26Buy1.424,000,0005,680,00012,000,000Apr 13 07:19 AM
George GregoryDirectorApr 10 '26Buy1.482,324,0723,439,6278,324,072Apr 13 07:19 AM
George GregoryDirectorApr 09 '26Buy1.441,586,8902,277,35013,586,890Apr 13 07:19 AM
George GregoryDirectorApr 09 '26Buy8.591,981,89017,015,46713,586,890Apr 10 07:27 PM
George GregoryDirectorApr 04 '26Buy1.424,000,0005,680,00012,000,000Apr 10 07:27 PM
George GregoryDirectorApr 10 '26Buy1.482,324,0723,439,6278,324,072Apr 10 07:27 PM
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.
FACRADr. Silviu Itescu FACP
M.B.A.Mr. James Michael O'Brien CPA
Global Head of Corporate Communications & Joint Company SecretaryMr. Paul Hughes BPHARM
Head of Human ResourcesMr. Anthony Wheal
Ph.D.Dr. Paul J. Simmons BSc